+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Global Psoriasis Drugs Market-Growth, Trends, and Forecasts 2017 - 2022

  • ID: 4388605
  • Report
  • Region: Global
  • 211 pages
  • Mordor Intelligence
1 of 3
The global psoriasis drugs market accounted for USD XX million in 2015 and USD XX million in 2016. The market is expected to reach USD XX million by 2021, growing at a CAGR of XX% during the forecast period from 2016 to 2021.

Psoriasis affects between 1% and 5% of the global population. About 30% of people with psoriasis have a family history of the condition, and certain genes have been linked to psoriasis. According to the Arthritis Foundation, the prevalence of psoriatic arthritis in patients suffering from psoriasis is approximately between 7% and 48%. Genetic factors explain that 40% of the psoriatic arthritis patients have a family history of skin and joint diseases.

Global Psoriasis Drugs Market-Market Dynamics

The report details several factors driving and restraining the market. Some of these are discussed below. There is a huge competition in drugs for psoriasis. Amgen biosimilar matches AbbVie's Humira in psoriasis trial. Humira, one of the leading drugs in psoriasis, earns almost two-thirds of the revenue for AbbVie.


Increasing investment in R&D of psoriasis, increasing expenditure on healthcare, the high unmet need for efficacious drug and long-lasting therapies are key factors propelling the growth of the market.


Increasing cost of R&D, drugs going off patent, and increasing generic products are turning out to be restraints for the market.

The psoriatic drugs market has been segmented based on the type of treatment, mechanism of action, route of administration and geography. Based on the type of treatment, the market has been segmented into biologic drugs, small molecule systemic drugs, and tropical therapies. Based on the mechanism of action, the market has been segmented into TNF inhibitors, PDE4 inhibitors, interleukin blockers. Based on the route of administration, these devices are categorized as oral, parenteral and topical. The TNF inhibitors include Etanercept (Enbrel), Certolizumab pegol (Cimzia), Adalimumab (Humira), infliximab (Remicade), Golimumab (Simponi). The PDE4 inhibitors include Apremilast and others. The interleukin blockers include Secukinumab (Cosaentyx) and others.

The market has been geographically segmented into North America, Europe, Asia-Pacific, Middle East & Africa and South America. The North American region has been further segmented into the USA, Canada, and Mexico. The Europe region has been sub-divided into Germany, France, the UK, Spain, Italy, Scandinavia, Benelux and Rest of Europe. The Asia-Pacific market has been segmented into Japan, China, India, South Korea, Australia & New Zealand and Rest of Asia-Pacific. The Middle East & African market has been subdivided into the GCC countries, South Africa and Rest of the Middle East and Africa. The South American market has been segmented into Brazil, Argentina, and Rest of South America. North America accounts for the largest market share.

The current market has a lot of competition between novel therapies by various firms and the one with a long lasting mechanism will have the scope to capture the market.

Major Companies in the Sector Include:

This Report Offers:

Market analysis for the global psoriasis drugs market, with region-specific assessments and competition analysis.

Market definition along with the identification of key drivers and restraints.

Identification of factors instrumental in changing the market scenario, rising prospective opportunities, and identification of key companies that can influence this market on a regional scale.

Extensively researched competitive landscape section with profiles of major companies along with their market share.

Identification and analysis of the macro and micro factors that affect global psoriasis drug market.

A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.

A wide-ranging knowledge and insights about the major players in this industry and the key strategies adopted by them to sustain and grow in the studied market.

Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped.
Note: Product cover images may vary from those shown
2 of 3
1. Introduction
1.1 Study Deliverables
1.2 Market Definition
1.3 Sizing Units
1.4 Base Currency
1.5 Review and Forecast Period Years
1.6 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Analysis Methodology
2.3 Study Timeline
2.4 Study Phases
2.4.1 Secondary Research
2.4.2 Discussion Guide
2.4.3 Market Engineering & Econometric Model
2.4.4 Expert Validation
3. Executive Summary
4. Key Inferences
5. Market Overview and Industry Trends
5.1 Current Market Scenario
5.2 Porters Five Force Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Buyers
5.2.3 Degree of Competition
5.2.4 Threat of Substitution
5.2.5 Threat of New Entrants
6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Increasing demand, higher onset of diseases
6.1.2 Increasing novel therapies
6.1.3 Increasing uptake of biosimilars and advanced therapies
6.1.4 Expansion of existing therapies
6.2 Market Restraints
6.2.1 Increasing demand for long-lasting therapies
6.2.2 Huge competition
6.3 Market Opportunities
6.3.1 New target populations shift from established markets to lesser developed markets
6.4 Key Challenges
6.4.1 Competition by novel therapies
7. Global Psoriasis Drug Market -Segmentation
7.1 Based On Type of Treatment
7.1.1 Biologic Drugs
7.1.2 Small Molecule Systemic Drugs
7.1.3 Tropical Therapies
7.2 Based On Mechanism of Action
7.2.1 TNF Inhibitors Etanercept (Enbrel) Certolizumab Pegol(Cimzia) Adalimumab (Humira) Infiximab (Remicade) Golimumab (Simponi )
7.2.2 PDE4 Inhibitors Apremilast (Otezla)
7.2.3 Interleukin Blockers Secukinumab (Cosentyxâ„¢)
7.3 Based on Route of Administration
7.3.1 Oral
7.3.2 Parenteral
7.3.3 Topical
8. Global Psoriasis Disease Drug Market by Geography - Regional Shares and Forecasts
8.1 North America
8.1.1 United States
8.1.2 Canada
8.1.3 Mexico
8.2 Europe
8.2.1 Germany
8.2.2 UK
8.2.3 France
8.2.4 Italy
8.2.5 Spain & Portugal
8.2.6 Scandinavia
8.2.7 Benelux
8.2.8 Rest of Europe
8.3 Asia-Pacific
8.3.1 China
8.3.2 Japan
8.3.3 India
8.3.4 Australia & New Zealand
8.3.5 South Korea
8.3.6 Rest of Asia-Pacific
8.4 Middle East and Africa
8.4.1 GCC
8.4.2 South Africa
8.4.3 Rest of the Middle East and Africa
8.5 Latin America
8.5.1 Brazil
8.5.2 Argentina
8.5.3 Rest of Latin America
9. Competitive Landscape
9.1 Merger and Acquisition Analysis
9.2 New Product Launches
9.3 Agreements, Collaborations & Partnerships
10. Company Profiles
10.1 Eli Lilly
10.2 Pfizer Inc.
10.3 Janssen Biotech, Inc.
10.4 Celgene Corporation
10.5 Takeda Pharmaceutical Company Limited
10.6 Stiefel Laboratories Inc.
10.7 Novartis AG
10.8 Amgen Inc.
10.9 Biogen Idec
10.10 AbbVie Inc.
11. Analyst Outlook for Investment Opportunities
12. Future Outlook of the Market
Note: Product cover images may vary from those shown
3 of 3